Business Wire

Veeva Vault PromoMats to Support Bristol Myers Squibb in Speeding Compliant Content to Market Engagement

17.11.2020 10:03:00 EET | Business Wire | Press release

Share

Veeva Systems (NYSE: VEEV) today announced that Bristol Myers Squibb (NYSE: BMY) is adopting Veeva Vault PromoMats to deliver fast, compliant content across all digital channels to meet their customers’ needs. Vault PromoMats will enable Bristol Myers Squibb to automatically generate submission-ready forms for 2253 and accelerated approval products, a new capability planned for availability in December 2020. The leading biopharmaceutical company can significantly reduce time in packaging promotional materials to send via Electronic Common Technical Document (eCTD) to the U.S. Food and Drug Administration.

Adoption of Vault PromoMats builds upon Bristol Myers Squibb’s success with other Veeva Commercial Cloud applications, including Veeva CRM, Veeva CRM Engage Meeting, Veeva CRM Approved Email, Veeva CRM Events Management, and Veeva Vault MedComms. Veeva gives Bristol Myers Squibb the commercial foundation for compliant content and multichannel engagement to drive a more tailored customer experience.

Vault PromoMats is an advanced application that combines digital asset management with medical, legal, and regulatory review to improve global reuse of promotional materials and maintain compliance from content creation through distribution. With Vault PromoMats, Veeva is helping life sciences stay ahead of evolving regulations, including the June 2021 deadline that will require organizations to submit promotional materials electronically with the latest eCTD requirements.

“We’re proud to continue our partnership with Bristol Myers Squibb and help promotional materials get to market efficiently in the face of a growing volume of content, channels, and complexity,” said Pooja Ojala, vice president of commercial content at Veeva. “Veeva is dedicated to product excellence and rapid innovation that helps leaders like Bristol Myers Squibb stay compliant while delivering a more impactful experience for their customers.”

Learn how Vault PromoMats speeds compliant commercial content to market at the upcoming Veeva Commercial & Medical Europe Summit Online, 17-18 Nov., 2020. The online event is open to life sciences industry professionals. Register and see the full agenda at veeva.com/Summit.

Additional Information

Connect with Veeva on LinkedIn: linkedin.com/company/veeva-systems
Follow @veeva_eu on Twitter: twitter.com/veeva_eu
Like Veeva on Facebook: facebook.com/veevasystems

About Veeva Systems

Veeva Systems Inc. is a leader in cloud solutions—including data, software, and services—for the global life sciences industry. Committed to innovation, product excellence, and customer success, Veeva serves more than 900 customers, ranging from the world's largest pharmaceutical companies to emerging biotechs. The company is headquartered in the San Francisco Bay Area, with offices throughout North America, Europe, Asia, and Latin America. For more information, visit veeva.com/eu.

Forward-looking Statements

This release contains forward-looking statements, including the market demand for and acceptance of Veeva’s products and services, the results from use of Veeva’s products and services, and general business conditions (including the on-going impact of COVID-19), particularly within the life sciences industry. Any forward-looking statements contained in this press release are based upon Veeva’s historical performance and its current plans, estimates, and expectations, and are not a representation that such plans, estimates, or expectations will be achieved. These forward-looking statements represent Veeva’s expectations as of the date of this press announcement. Subsequent events may cause these expectations to change, and Veeva disclaims any obligation to update the forward-looking statements in the future. These forward-looking statements are subject to known and unknown risks and uncertainties that may cause actual results to differ materially. Additional risks and uncertainties that could affect Veeva’s financial results are included under the captions, “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations,” in the company’s filing on Form 10-Q for the period ended July 31, 2020. This is available on the company’s website at veeva.com under the Investors section and on the SEC’s website at sec.gov. Further information on potential risks that could affect actual results will be included in other filings Veeva makes with the SEC from time to time.

® 2020 Veeva Systems Inc. All rights reserved. Veeva and the Veeva logo are trademarks of Veeva Systems Inc.
Veeva Systems Inc. owns other registered and unregistered trademarks.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Roger Villareal
Veeva Systems
925-264-8885
roger.villareal@veeva.com

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

BeOne Medicines Announces Voluntary Agreement with U.S. Government to Expand Access to Innovative Cancer Medicines31.8.2026 22:00:00 EEST | Press release

BeOne Medicines, Ltd. (Nasdaq: ONC; HKEX: 06160; SSE: 688235), a global oncology company, today announced a voluntary agreement with the U.S. Government to expand access to innovative cancer medicines for American patients while strengthening our U.S manufacturing footprint and further expanding the capabilities needed to deliver medicines at scale. The agreement builds on BeOne's longstanding commitment to patient access and investment in research and scientific innovation. John V. Oyler, Co-Founder, Chairman and CEO, BeOne Medicines, said: “At BeOne, we believe every patient should benefit from innovative cancer therapies. We appreciate the Trump Administration’s commitment to advancing solutions that broaden access and scientific progress for American patients. This agreement reflects our purpose to reach more patients as we expand our U.S. investment in additional research, development, and manufacturing to deliver breakthrough cancer treatments worldwide.” Improved access to oncol

MEX Exchange, Part of MultiBank Group, Announces Senior Leadership Appointments31.8.2026 16:36:00 EEST | Press release

MEX Exchange, the institutional electronic trading platform of MultiBank Group, has announced two senior leadership appointments, with David Ogg promoted to Vice Chairman and Brian Andreyko promoted to Chief Executive Officer. The appointments strengthen the company’s leadership as it advances the development of its institutional electronic trading platform. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831401493/en/ MEX Exchange, part of MultiBank Group, Announces Senior Leadership Appointments with David Ogg appointed Vice Chairman and Brian Andreyko named CEO. David Ogg brings more than four decades of experience in foreign exchange trading and trading technology and is widely recognised within the institutional FX industry as the “Father of the ECN.” He founded HotspotFX in 1999, the first institutional FX electronic communications network, before going on to establish LavaFX and Ogg Trading. His career has also incl

Rimini Street Announces Stock Repurchase and Debt Reduction Transactions31.8.2026 16:00:00 EEST | Press release

Rimini Street, Inc., (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced additional, recent capital return and balance sheet optimization actions as noted below during the fiscal third quarter through August 28, 2026: This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831961587/en/ Rimini Street Announces Stock Repurchase and Debt Reduction Transactions Debt Reduction: The Company prepaid $5.0 million of its term loan and has reduced term loan debt by a total of $25.9 million fiscal year-to-date, reducing the outstanding balance to $43.4 million. Share Repurchases: The Company repurchased 970,566 shares of its common stock at an average price of $5.16 per share for an aggregate cost of approximately $5.0 million. “Our year-to-date share repurchases

rhode Announces Official Launch Date for Its Retail Expansion in Europe with Sephora31.8.2026 16:00:00 EEST | Press release

rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), today announced its collection of high-performance, skin-focused products will be available at Sephora online and in most stores across Europe starting Wednesday, 30 September, 2026, following its 2025 rollout with Sephora in the U.S., Canada, and the U.K. This expansion with Sephora in Europe increases global access to rhode through physical retail, marking a pivotal next stage for the brand. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831869746/en/ rhode will be available at Sephora online and in most stores across Europe starting Wednesday, 30 September, 2026 Launched in June 2022, rhode began with a curated lineup of efficacious skincare, expanding into hybrid makeup. Each launch has garnered tremendous demand, inspiring shifts across the beauty industry and culture at large. Today, rhode remains the No.1 overall skincare

Laboratory Modernization Strengthens QPS Holdings, LLC’s Long-Term Commitment to Elemental Bioanalysis31.8.2026 16:00:00 EEST | Press release

QPS Holdings, LLC (QPS) today announced a significant renewal of its elemental bioanalysis infrastructure through the acquisition of two PerkinElmer NexION® 2200 inductively coupled plasma mass spectrometry (ICP-MS) systems to be housed in its Netherlands laboratories. The new instruments will replace two Agilent 7700 ICP-MS systems currently operating within the bioanalysis department. The NexION® 2200 platform was selected to support robust trace-element analysis, effective management of analytical interferences, reliable performance with challenging sample matrices, and efficient laboratory operations. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260831322534/en/ Daniel Schulz-Jander, QPS Senior Director, Bioanalysis The investment is part of a broader upgrade and renewal program focused on maintaining a modern, reliable, and sustainable mass spectrometry capabilities across QPS global laboratory facilities. In addition

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye